Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial.
Kamata K, Imai H, Matsumoto H, Yamashita Y, Kato T, Nishi K, Omoto S, Minaga K, Yamao K, Hyodo T, Im SW, Hara A, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Ueshima K, Chiba Y, Takenaka M, Watanabe T, Kitano M, Kudo M. Kamata K, et al. Among authors: kudo m. JGH Open. 2023 Sep 7;7(9):659-666. doi: 10.1002/jgh3.12966. eCollection 2023 Sep. JGH Open. 2023. PMID: 37744711 Free PMC article.
Serum leucine-rich alpha-2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy-naïve cases with ulcerative colitis.
Kono M, Komeda Y, Tribonias G, Yoshida S, Nomura K, Handa K, Nagai T, Hagiwara S, Omoto S, Takenaka M, Nishida N, Tsuji N, Kashida H, Kudo M. Kono M, et al. Among authors: kudo m. JGH Open. 2023 Aug 3;7(8):579-583. doi: 10.1002/jgh3.12953. eCollection 2023 Aug. JGH Open. 2023. PMID: 37649867 Free PMC article.
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N. Kudo M, et al. Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep. Liver Cancer. 2023. PMID: 37901197 Free PMC article.
Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N. Aoki T, et al. Among authors: kudo m. Liver Cancer. 2023 May 11;13(1):56-69. doi: 10.1159/000531024. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344443 Free PMC article.
2,477 results